Annovis Bio (NYSE:ANVS) Releases Earnings Results, Misses Estimates By $0.05 EPS

Annovis Bio (NYSE:ANVS) posted its earnings results on Friday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05), Zacks reports. During the same quarter in the previous year, the firm earned ($0.43) earnings per share.

Annovis Bio Stock Performance

Annovis Bio stock opened at $1.77 on Friday. Annovis Bio has a 1 year low of $1.53 and a 1 year high of $20.00. The firm has a market cap of $25.13 million, a price-to-earnings ratio of -0.40 and a beta of 1.65. The firm’s 50 day moving average price is $2.99 and its two-hundred day moving average price is $5.76.

Analyst Ratings Changes

Separately, D. Boral Capital reiterated a “hold” rating on shares of Annovis Bio in a report on Monday, February 10th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Annovis Bio has a consensus rating of “Buy” and an average price target of $37.00.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.